These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18753927)

  • 1. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
    Van Baelen K; Van Eygen V; Rondelez E; Stuyver LJ
    AIDS; 2008 Sep; 22(14):1877-80. PubMed ID: 18753927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.
    Van Baelen K; Rondelez E; Van Eygen V; Ariën K; Clynhens M; Van den Zegel P; Winters B; Stuyver LJ
    J Virol Methods; 2009 Nov; 161(2):231-9. PubMed ID: 19559730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
    Ceccherini-Silberstein F; Van Baelen K; Armenia D; Trignetti M; Rondelez E; Fabeni L; Scopelliti F; Pollicita M; Van Wesenbeeck L; Van Eygen V; Dori L; Sarmati L; Aquaro S; Palamara G; Andreoni M; Stuyver LJ; Perno CF
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3938-48. PubMed ID: 20479206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
    Cavaco-Silva J; Abecasis A; Miranda AC; Poças J; Narciso J; Águas MJ; Maltez F; Almeida I; Germano I; Diniz A; Gonçalves Mde F; Gomes P; Cunha C; Camacho RJ;
    PLoS One; 2014; 9(3):e92747. PubMed ID: 24681625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
    Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural polymorphisms of integrase among HIV type 1-infected South African patients.
    Fish MQ; Hewer R; Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):489-93. PubMed ID: 20377427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
    Raffi F; Wainberg MA
    Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
    Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
    AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance to integrase inhibitors].
    Garrido C; de Mendoza C; Soriano V
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():40-6. PubMed ID: 19572425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
    Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
    Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
    Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
    AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
    Alessandri-Gradt E; Collin G; Tourneroche A; Bertine M; Leoz M; Charpentier C; Unal G; Descamps D; Plantier JC
    J Antimicrob Chemother; 2017 Sep; 72(9):2431-2437. PubMed ID: 28859447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.